Market research
AVIR Atea Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 436M
- P/E ratio
- Not available
- Analyst target
- 9.4167
- Dividend yield
- Not available
- Beta
- 0.27
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US04683R1068
- Market cap
- 436M
- P/E ratio
- Not available
- Analyst target
- 9.4167
- Dividend yield
- Not available
- Beta
- 0.27
About
About Atea Pharmaceuticals Inc
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the AVIR discussion.
5 years, 4 months ago
From a valuation standpoint, the stock is 98.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 25.7.
Based on the above factors, Atea Pharmaceuticals, Inc gets an overall score of 1/5.